PARK CITY, Utah, Oct. 10 /PRNewswire/ -- NuView Life Sciences Inc. (NuView) has agreed to assume management of Trace Life Sciences Inc. (Trace), including operations of the linear accelerator and cyclotron production facilities in Denton, Texas. The Trace facility produces Copper-64, Copper- 67, Indium-111, Iodine-123 and Thallium-201 used in molecular imaging and nuclear medicine. Paul Crowe, NuView Chairman and CEO, stated that "We are confident that by improving operational efficiencies at Trace, combined with our national sales force, we will provide customers a viable resource for their clinical needs." Added NuView's Chief Medical Officer Peter Conti, M.D., Ph.D., FACR, FACNP, "Using the unique capabilities of this facility, we anticipate the ability to produce novel radioisotopes to satisfy unmet needs of the research community."
About NuView Life Sciences Inc.
NuView Life Sciences Inc., a Utah-based life-sciences company, is focused on identifying and developing emerging novel diagnostic or targeted therapies. NuView partners with private enterprise and university-based researchers whom it believes have developed promising new products which may offer significant improvement over current diagnostic or therapeutic approaches for cardiology and cancer disorders. NuView also distributes approved pharmaceutical and medical-device products routinely utilized in clinical practice today. For more information about NuView, please call 866-577-7764 or visit http://www.nuviewinfo.com.
CONTACT: Bruce Fryer, +1-435-655-2732, for NuView Life Sciences Inc.
Web site: http://www.nuviewinfo.com/
